[go: up one dir, main page]

SI2849740T1 - Farmacevtski sestavek, ki obsega (1r,4r)-6'-fluoro-N,N-dimetil-4-fenil- 4',9'-dihidro-3'H-spiro(cikloheksan-1,1'-pirano(3,4,b)indol)-4-amin in paracetamol ali propacetamol - Google Patents

Farmacevtski sestavek, ki obsega (1r,4r)-6'-fluoro-N,N-dimetil-4-fenil- 4',9'-dihidro-3'H-spiro(cikloheksan-1,1'-pirano(3,4,b)indol)-4-amin in paracetamol ali propacetamol Download PDF

Info

Publication number
SI2849740T1
SI2849740T1 SI201330870T SI201330870T SI2849740T1 SI 2849740 T1 SI2849740 T1 SI 2849740T1 SI 201330870 T SI201330870 T SI 201330870T SI 201330870 T SI201330870 T SI 201330870T SI 2849740 T1 SI2849740 T1 SI 2849740T1
Authority
SI
Slovenia
Prior art keywords
active ingredient
pharmacologically active
pain
pharmaceutical composition
pharmaceutical
Prior art date
Application number
SI201330870T
Other languages
English (en)
Inventor
Stefanie Frosch
Klaus Linz
Klaus Schiene
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of SI2849740T1 publication Critical patent/SI2849740T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Claims (13)

  1. EP 2849740 BI Farmacevtski sestavek, ki obsega (lr,4r)-6’-fluoro-N,N-dimetil-4-fenil-4’,9,-dihidro-3’H-spiro[cikloheksan-l,r-pirano[3,4,b]indol]-4-amin in paracetamol ali propacetamol Patentni zahtevki
    1. Farmacevtski sestavek, ki obsega: (a) prvo farmakološko aktivno sestavino, izbrano izmed spojine s splošno formulo (I) in fiziološko sprejemljivih soli le-te
    (I) in (b) drugo farmakološko aktivno sestavino, izbrano izmed paracetamola ali propacetamola.
  2. 2. Farmacevtski sestavek po zahtevku 1, kjer je prva farmakološko aktivna sestavina kemična spojina s formulo (I):
    (I) v obliki hidrokloridne, hemicitratne ali maleatne soli.
  3. 3. Farmacevtski sestavek po zahtevku 1 ali 2, kjer je druga farmakološko aktivna sestavina paracetamol.
  4. 4. Farmacevtski sestavek po katerem koli od prejšnjih zahtevkov, kjer je relativno masno razmerje prve farmakološko aktivne sestavine proti drugi farmakološko aktivni sestavini v območju od 1 : 30 do 1 : 1 000 000.
  5. 5. Farmacevtski sestavek po katerem koli od prejšnjih zahtevkov za uporabo pri preprečevanju ali zdravljenju bolečine.
  6. 6. Farmacevtski sestavek po zahtevku 5, kjer je bolečina: - periferna, centralna ali mišičnoskeletna bolečina; in/ali - akutna, subakutna ali kronična bolečina; in/ali - zmerna do huda bolečina; in/ali - nevropatska ali psihogena ali nociceptivna ali mešana bolečina; in/ali - bolečina v križu, visceralna bolečina ali glavobol; in/ali - pooperacijska (pokirurška) bolečina, bolečina zaradi raka ali vnetna bolečina.
  7. 7. Farmacevtska odmema oblika, ki obsega farmacevtski sestavek po katerem koli od prejšnjih zahtevkov.
  8. 8. Farmacevtska odmema oblika po zahtevku 7, ki vsebuje prvo farmakološko aktivno sestavino v odmerku 10-1200 pg.
  9. 9. Farmacevtska odmema oblika po zahtevku 7 ali 8, ki vsebuje drugo farmakološko aktivno sestavino v odmerku 100-8 000 mg.
  10. 10. Farmacevtska odmema oblika po katerem koli od zahtevkov 7-9, kjer je odmerek prve farmakološko aktivne sestavine v območju od 1 : 20 do 20 : 1 količine, ki je enako učinkovita kot odmerek druge farmakološko aktivne sestavine.
  11. 11. Farmacevtska odmema oblika po katerem koli od zahtevkov 7-10, ki je za peroralno, intravenozno, intraperitonealno, transdermalno, intratekalno, intramuskulamo, intranazalno, transmukozno, subkutano ali rektalno dajanje.
  12. 12. Komplet, ki obsega prvo farmacevtsko odmemo obliko, ki obsega prvo farmakološko aktivno sestavino, kot je definirana v zahtevku 1 ali 2, in drugo farmacevtsko odmemo obliko, ki obsega drago farmakološko aktivno sestavino, kot je definirana v zahtevku 1 ali 3.
  13. 13. Komplet po zahtevku 12, kjer sta prva in druga farmacevtska odmema oblika prilagojeni za sočasno ali zaporedno dajanje, bodisi na enak ali drugačen način dajanja.
SI201330870T 2012-05-18 2013-05-16 Farmacevtski sestavek, ki obsega (1r,4r)-6'-fluoro-N,N-dimetil-4-fenil- 4',9'-dihidro-3'H-spiro(cikloheksan-1,1'-pirano(3,4,b)indol)-4-amin in paracetamol ali propacetamol SI2849740T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12003897 2012-05-18
PCT/EP2013/001468 WO2013170969A1 (en) 2012-05-18 2013-05-16 Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano'[3,4,b]indol]-4-amine and paracetamol or propacetamol
EP13723674.1A EP2849740B1 (en) 2012-05-18 2013-05-16 Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano'[3,4,b]indol]-4-amine and paracetamol or propacetamol

Publications (1)

Publication Number Publication Date
SI2849740T1 true SI2849740T1 (sl) 2018-01-31

Family

ID=48468208

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201330870T SI2849740T1 (sl) 2012-05-18 2013-05-16 Farmacevtski sestavek, ki obsega (1r,4r)-6'-fluoro-N,N-dimetil-4-fenil- 4',9'-dihidro-3'H-spiro(cikloheksan-1,1'-pirano(3,4,b)indol)-4-amin in paracetamol ali propacetamol

Country Status (22)

Country Link
US (3) US20130310435A1 (sl)
EP (1) EP2849740B1 (sl)
JP (1) JP6116676B2 (sl)
CN (2) CN104302282A (sl)
AU (1) AU2013262075B2 (sl)
BR (1) BR112014028561A2 (sl)
CA (1) CA2873644A1 (sl)
CY (1) CY1119610T1 (sl)
DK (1) DK2849740T3 (sl)
EA (1) EA026949B1 (sl)
ES (1) ES2650441T3 (sl)
HR (1) HRP20171438T1 (sl)
HU (1) HUE034676T2 (sl)
IL (1) IL235651B (sl)
LT (1) LT2849740T (sl)
MX (1) MX352596B (sl)
NO (1) NO2849740T3 (sl)
PL (1) PL2849740T3 (sl)
PT (1) PT2849740T (sl)
RS (1) RS56617B1 (sl)
SI (1) SI2849740T1 (sl)
WO (1) WO2013170969A1 (sl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10022353B2 (en) 2015-01-23 2018-07-17 Grünenthal GmbH Cebranopadol for treating pain in subjects with impaired hepatic and/or impaired renal function
JP7373904B2 (ja) 2016-02-29 2023-11-06 パーク・セラピューティクス・インコーポレイテッド セブラノパドールの滴定

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0068838B1 (en) 1981-06-26 1986-09-17 The Upjohn Company Analgesic process and composition
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4404208A (en) 1982-06-30 1983-09-13 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and tiflamizole
IE55189B1 (en) 1982-07-08 1990-06-20 Wyeth John & Brother Ltd Pharmaceutical compositions
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
DE3665538D1 (en) 1985-01-23 1989-10-19 Asta Pharma Ag Synergistic combination of flupirtin and non-steroidal anti-phlogistics
EP0473655B1 (en) 1989-05-22 1997-01-15 Biochemical Veterinary Research Pty. Ltd. Divalent metal salts of indomethacin
CA2112378A1 (en) 1991-07-04 1993-01-21 Masakazu Kanazawa Analgesic preparation
JPH05221857A (ja) * 1992-02-14 1993-08-31 Arakusu:Kk 配合解熱鎮痛剤
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5330761A (en) 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
AU680020B2 (en) 1993-06-07 1997-07-17 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin antagonists
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5399362A (en) 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
US5914129A (en) 1996-07-23 1999-06-22 Mauskop; Alexander Analgesic composition for treatment of migraine headaches
RS49982B (sr) 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
TR200100708T2 (tr) 1998-09-10 2001-07-23 Nycomed Danmark A/S İlaç maddelerine mahsus çabuk salımlı farmasötik bileşimler.
WO2000028980A2 (en) 1998-11-13 2000-05-25 Eli Lilly And Company Combination of duloxetine with non-steroidal antiinflammatory drug for treating pain
DE50104197D1 (de) 2000-12-28 2004-11-25 Fresenius Kabi Austria Gmbh Gr Stabile Infusionslösung von Diclofenac-Salzen, deren Herstellung und Verwendung
WO2003064425A1 (en) 2002-01-28 2003-08-07 Pfizer Japan Inc. N-substituted spiropiperidine compounds as ligands for orl-1 receptor
DE60219609T2 (de) 2002-06-17 2008-01-03 Chiesi Farmaceutici S.P.A. Prozess für die Vorbereitung von Piroxicam: Beta-Cyclodextrin Einschlusskomplexe
DE10252667A1 (de) * 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE10257824B4 (de) 2002-12-10 2004-11-11 Kochem, Hans-Günter, Dr. Zusammensetzung zur Schmerzbehandlung, insbesondere zur Behandlung von Gelenkschmerzen
US20100297252A1 (en) 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
US7132452B2 (en) 2003-03-10 2006-11-07 Fang-Yu Lee Topical formulation having effects on alleviating pain/inflammation caused by herpes virus infection
DE10360792A1 (de) 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
CN101198606A (zh) 2005-06-17 2008-06-11 辉瑞有限公司 作为ORL1-受体拮抗剂的α-(芳基-或杂芳基-甲基-)-β哌啶子基丙酰胺化合物
EP2012764B1 (en) * 2006-04-28 2011-01-12 Grünenthal GmbH Pharmaceutical combination comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol and paracetamol
PT2012763E (pt) 2006-04-28 2011-04-29 Gruenenthal Gmbh Combinação farmacêutica que compreende 3-(3-dimetilamino-1-etil-2-metil-propil)fenol e um aine
CN101147735A (zh) * 2006-09-19 2008-03-26 沈阳华泰药物研究有限公司 注射用药物组合物及其药盒
DE102006046745A1 (de) * 2006-09-29 2008-04-03 Grünenthal GmbH Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz
DE102006056458A1 (de) * 2006-11-28 2008-05-29 Grünenthal GmbH Arzneimittelzubereitung von Tramadol und Acetaminophen
CA2701838A1 (en) 2007-10-09 2009-04-16 Merck Patent Gmbh Pharmaceutical compositions containing benfotiamine and one or more pharmaceutically active agents for the treatment of pain conditions of neuropathic origin
CN100560061C (zh) 2008-06-20 2009-11-18 海南锦瑞制药股份有限公司 一种氯诺昔康冻干粉针剂及其制备方法
AR073495A1 (es) 2008-09-05 2010-11-10 Gruenenthal Gmbh Combinacion farmaceutica que contiene el 6-dimetilaminometil-1- (3-metoxi-fenil)-ciclohexano-1,3-diol y un nsaid
NZ591419A (en) 2008-09-05 2011-11-25 Gruenenthal Chemie Pharmaceutical combination comprising 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3 diol and paracetamol
KR101851120B1 (ko) * 2008-09-05 2018-04-23 그뤼넨탈 게엠베하 3-（3-디메틸아미노-1-에틸-2-메틸-프로필）-페놀과 항간질제의 약제학적 병용물
MX2013000980A (es) * 2010-08-04 2013-02-15 Gruenenthal Gmbh Forma de dosificacion farmaceutica que comprende 6'-fluoro-(n-metil- o n, n-dimetil-)-4-fenil-4', 9'-dihidro-3'h-espiro [ciclohexan-1, 1'-pirano[3, 4, b]indol]-4-amina.
AU2011287955B2 (en) * 2010-08-04 2015-07-09 Grünenthal GmbH Pharmaceutical dosage form comprising 6'-fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain
EP2600846B1 (en) * 2010-08-04 2015-11-25 Grünenthal GmbH Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cylohexane-1,1'-pyrano[3,4,b]indol]-4-amine
US9320729B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative

Also Published As

Publication number Publication date
ES2650441T3 (es) 2018-01-18
JP2015516449A (ja) 2015-06-11
JP6116676B2 (ja) 2017-04-19
HRP20171438T1 (hr) 2017-11-03
HUE034676T2 (hu) 2018-02-28
CN108524498A (zh) 2018-09-14
MX2014012723A (es) 2015-01-15
EP2849740B1 (en) 2017-09-13
CA2873644A1 (en) 2013-11-21
WO2013170969A1 (en) 2013-11-21
LT2849740T (lt) 2017-12-27
CN104302282A (zh) 2015-01-21
CY1119610T1 (el) 2018-04-04
US11311504B2 (en) 2022-04-26
AU2013262075B2 (en) 2017-10-26
MX352596B (es) 2017-11-30
IL235651A0 (en) 2015-01-29
IL235651B (en) 2018-08-30
US20130310435A1 (en) 2013-11-21
US20180092867A1 (en) 2018-04-05
EP2849740A1 (en) 2015-03-25
BR112014028561A2 (pt) 2017-07-25
HK1204940A1 (en) 2015-12-11
PT2849740T (pt) 2017-12-13
NO2849740T3 (sl) 2018-02-10
US20190350884A1 (en) 2019-11-21
EA026949B1 (ru) 2017-06-30
AU2013262075A1 (en) 2015-01-22
EA201401272A1 (ru) 2015-05-29
PL2849740T3 (pl) 2018-03-30
DK2849740T3 (da) 2017-11-20
RS56617B1 (sr) 2018-02-28

Similar Documents

Publication Publication Date Title
MX2013012588A (es) Inhibidores de cinasa.
MY149731A (en) Compounds
JP2013542247A5 (sl)
MX2012001872A (es) Formulaciones intravenosas de antagonistas de neurocinina 1.
WO2013004995A8 (en) Pyrimidinone compounds and their use
NZ702826A (en) Oral formulations and lipophilic salts of methylnaltrexone
IN2014DN05869A (sl)
HRP20151327T1 (hr) Farmaceutska kombinacija za lijeäśenje boli
UA99914C2 (ru) Способ применения антагонистов вазопресина со средствами антрациклиновой химиотерапии для снижения кардиотоксичности
HK1209741A1 (en) Tricyclic compounds for inhibiting the cftr channel
WO2011159100A3 (ko) 항암 활성을 나타내는 약제학적 조성물
EA201591175A1 (ru) Трициклические соединения в качестве ингибиторов cftr
HRP20171693T1 (hr) Farmaceutski pripravak koji sadrži (1r, 4r)-6'-fluoro-n,n-dimetil-4-fenil-4',9'-dihidro-3'h-spiro[cikloheksan-1,1'-pirano-[3,4,b]indol]-4-amin i ibuprofen
EA201291014A1 (ru) Трициклическое индазольное соединение, способ его получения и содержащая его фармацевтическая композиция
SI2849748T1 (sl) Farmacevtski sestavek, ki obsega (1r,4r)-6'-fluoro-N,N-dimetil-4-fenil- 4',9'-dihidro-3'H-spiro(cikloheksan-1,1'-pirano(3,4,b)indol)-4-amin in gabapentinoid
TN2014000060A1 (en) Benzothiazolone compound
HK1215672A1 (zh) 用於治療炎症和癌症的吲哚類化合物
SI2849740T1 (sl) Farmacevtski sestavek, ki obsega (1r,4r)-6'-fluoro-N,N-dimetil-4-fenil- 4',9'-dihidro-3'H-spiro(cikloheksan-1,1'-pirano(3,4,b)indol)-4-amin in paracetamol ali propacetamol
SI2849746T1 (sl) Farmacevtski sestavek, ki obsega (1r,4r)-6'-fluoro-N,N-dimetil-4-fenil- 4',9'-dihidro-3'H-spiro(cikloheksan-1,1'-pirano-(3,4,b)indol)-4-amin in meloksikam
SI2849744T1 (sl) Farmacevtski sestavek, ki obsega (1r,4r)-6'-fluoro-N,N-dimetil-4-fenil-4',9'-dihidro-3'H-spiro(ciklo- heksan-1,1'-pirano-(3,4,b)indol)-4-amin in duloksetin
HRP20171725T1 (hr) FARMACEUTSKI PRIPRAVAK KOJI SADRŽI (1R,4R)-6'-FLUORO-N,N-DIMETIL-4-FENIL-4',9'-DIHIDRO-3'H-SPIRO[CIKLOHEKSAN-1,1'-PIRANO [3,4,b]INDOL]-4-AMIN I NSAR
IN2012CH01309A (sl)
SI2852386T1 (sl) Farmacevtska sestava, ki zajema (1r,4r)-6'-fluoro-n,n-dimetil-4-fenil- 4',9'-dihidro-3'h-spiro (cikloheksan-1,1'-pirano-(3,4,b)indol)-4-amin in acetilsalicilno kislino
WO2008136374A1 (ja) 抗癌剤投与に伴う末梢神経障害抑制用医薬組成物
WO2011094208A3 (en) Methods and pharmaceutical compositions for preventing and treating renal impairment